Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Estimated Market Size of the Human Immunodeficiency Virus Therapeutics Market In 2029?
The market for therapeutics concerning the human immunodeficiency virus has experienced significant growth in the past years. The market value predicted to increase from $14.11 billion in 2024 to $14.9 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 5.6%. The growth experienced in the prior period can be accredited to an increase in HIV prevalence, escalation in awareness programs, a surge in diagnostic testing, an increase in the penetration of generic drugs, and expansion of healthcare infrastructure.
The market for therapies dealing with the human immunodeficiency virus is predicted to experience significant expansion in the coming years. Forecasts predict that it will increase to a value of$18.44 billion by 2029 with a 5.5% compound annual growth rate (CAGR). This projected growth during the forecast period can be credited to a number of factors such as the escalating number of HIV patients, an increase in HIV testing, a rise in voluntary examinations, a surge in unprotected sexual practices, and the expansion of government initiatives. Leading trends for the forecast period encompass technological innovations, AI-powered drug discovery processes, long-acting injectable treatments, the integration of telemedicine, and the application of CRISPR for gene therapy.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23419&type=smp
What Are the Core Growth Drivers Propelling the Human Immunodeficiency Virus Therapeutics Market Forward?
The increasing occurrence of unprotected sexual activities is anticipated to fuel the expansion of the human immunodeficiency virus therapeutics market in the future. Unprotected sexual activities are those that do not involve barrier protection, leading to a heightened risk of sexually transmitted infections (STIs) and unplanned pregnancies. The absence of extensive sexual education results in limited knowledge about safe practices, which promotes risk-taking behaviour in young people. HIV therapeutics are instrumental in curbing the risk of HIV transmission from unprotected sexual activities by keeping the viral load at undetectable levels, thus preventing the virus’ further spread. For example, based on information from the Centers for Disease Control and Prevention, a government agency in the USA, a 2023 survey revealed that 32% of U.S. high school students admitted to having sexual intercourse at least once, with 48% stating they did not use a condom during their most recent sexual encounter. Hence, the increasing occurrence of unprotected sexual activities is spurring the expansion of the human immunodeficiency virus therapeutics market.
What Segment Types Define the Human Immunodeficiency Virus Therapeutics Market Structure?
The human immunodeficiency virus therapeuticsmarket covered in this report is segmented –
1) By Drug Type: Branded Drugs; Generic Drugs
2) By Drug Class: Nucleoside-Analog Reverse Transcriptase Inhibitors (Nrtis); Non-Nucleoside Reverse Transcriptase Inhibitors (Nnrtis); Entry And Fusion Inhibitors; Protease Inhibitors (Pis); Integrase Inhibitors; Coreceptor Antagonists
3) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies
4) By End-user: Hospitals And Clinics; Specialty Centers
Subsegments:
1) By Branded Drugs: Biktarvy; Triumeq; Genvoya; Juluca; Dovato; Isentress; Prezista
2) By Generic Drugs: Tenofovir Disoproxil Fumarate (TDF); Lamivudine; Efavirenz; Zidovudine; Nevirapine; Abacavir; Ritonavir
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=23419&type=smp
Which Geographic Areas Hold the Strongest Growth Potential in the Human Immunodeficiency Virus Therapeutics Market?
North America was the largest region in the human immunodeficiency virus therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human immunodeficiency virus therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Which Emerging Trends that Are Influencing theHuman Immunodeficiency Virus Therapeutics Industry Evolution?
Leading companies in the HIV therapeutics market are concentrating their efforts on introducing groundbreaking treatments such as combination therapy. This approach aims to enhance the efficacy of treatment, reduce drug resistance, and foster patient compliance by using multiple therapeutic agents to manage a single disease. The benefits of this method include improved treatment efficiency, reduced side effects, and a decreased likelihood of drug resistance. An example of this comes from Gilead Sciences Inc., a biopharmaceutical company from the US, which in December 2022, secured approval from the FDA for their Sunlenca (lenacapavir) treatment. When used in conjunction with other antiretroviral medications, Sunlenca can be administered to adults with multi-drug-resistant HIV-1. Sunlenca is distinguished for being the first HIV treatment which is based on a capsid inhibitor, presenting a twice-yearly dosing regimen for patients who have previously undergone extensive treatment. The approval of this treatment is backed by the positive results of the CAPELLA trial, which demonstrated high rates of long-term viral suppression. The innovative method of action and the long-lasting formulation of Sunlenca suggests that it will play a significant part in the future strategies for HIV treatment and prevention.
View the full report here:
What Is the Definition of the Human Immunodeficiency Virus Therapeutics Market?
Human immunodeficiency virus (HIV) therapeutics refer to medications and treatment strategies designed to manage and suppress HIV infection, primarily through antiretroviral therapy (ART). These therapeutics help reduce viral load, prevent disease progression to AIDS, and improve the quality of life for individuals living with HIV.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23419
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model